CpG-island fragments from the HNRPA2B1/CBX3genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells
© Williams et al; licensee BioMed Central Ltd. 2005
Received: 22 December 2004
Accepted: 03 June 2005
Published: 03 June 2005
The hCMV promoter is very commonly used for high level expression of transgenes in mammalian cells, but its utility is hindered by transcriptional silencing. Large genomic fragments incorporating the CpG island region of the HNRPA2B1 locus are resistant to transcriptional silencing.
In this report we describe studies on the use of a novel series of vectors combining the HNRPA2B1 CpG island with the hCMV promoter for expression of transgenes in CHO-K1 cells. We show that the CpG island gives at least twenty-fold increases in the levels of EGFP and EPO observed in pools of transfectants, and that transgene expression levels remain high in such pools for more than 100 generations. These novel vectors also allow facile isolation of clonal CHO-K1 cell lines showing stable, high-level transgene expression.
Vectors incorporating the hnRPA2B1 CpG island give major benefits in transgene expression from the hCMV promoter, including substantial improvements in the level and stability of expression. The utility of these vectors for the improved production of recombinant proteins in CHO cells has been demonstrated.
Despite recent progress in elucidating the molecular basis of gene expression the practicality of achieving reliable, stable, high-level transgene expression in mammalian cells remains a major challenge. This inefficiency of transgene expression is largely attributable to transcriptional silencing, which typically involves methylation at CpG DNA sequences, histone deacetylation and chromatin condensation in the vicinity of the integration site [1, 2]. When exogenous genes are introduced into cultured cells, many of the integration events lead to rapid transgene silencing, whilst the remainder give widely varying expression levels [3, 4]. For this reason the use of cultured mammalian cells to produce recombinant proteins (except at very small scale) usually requires labour-intensive isolation of rare, clonal cell lines that stably express the transgene at high levels. Similarly, chromatin structure-related silencing and extreme variability in expression hinder the use of transgenic animals for purposes such as defining novel gene function and manufacture of therapeutic proteins [5, 6]. Furthermore, achieving clinical utility with gene therapies (especially for chronic diseases), is greatly hindered by inadequate levels and duration of therapeutic transgene expression, resulting partly from transcriptional silencing [7, 8]. The identification of elements capable of maintaining a transcriptionally competent ("open") chromatin domain resistant to silencing, irrespective of tissue type or integration site, is therefore an important objective in the development of technology giving more efficient transgene expression in mammalian cells, for many important applications.
We have reported previously that large DNA fragments containing CpG islands from the human TBP-PSMB1 and HNRPA2B1-CBX3 loci (designated TBP and RNP below) are resistant to heterochromatin-mediated silencing of these genes . These regions are structurally similar, containing dual divergently transcribed promoters embedded within an extended methylation-free CpG island. The divergent promoters drive expression of ubiquitously expressed housekeeping genes, encoding the TATA binding protein and proteasome component-B1 in the case of the TBP locus, and the heterogeneous ribonucleoprotein A2/B1 and chromobox homolog 3 in the case of the RNP locus. Our previous studies showed that with these large CpG island-containing fragments, active transcription from the endogenous promoters was maintained even upon integration into centromeric heterochromatin, that single copy integration at different sites gave very similar levels of gene expression, and that position effect variegation was greatly reduced .
The endogenous promoters of the housekeeping genes at the TBP and RNP loci are relatively weak. In this paper we report studies with a series of novel expression vectors in which the CpG island from the RNP locus was combined with the immediate early promoter/enhancer of the human cytomegalovirus (hCMV), the promoter most commonly used to achieve strong, non-selective expression in mammalian cells for many applications. We show that the RNP CpG island confers major benefits in transgene expression from this promoter, including substantial improvements in the level of expression and proportion of transfected cells that express at detectable levels. We show that with these novel vectors expression remains high on prolonged subculturing. We also demonstrate the utility of these vectors for the improved production of recombinant proteins in Chinese Hamster Ovary (CHO) cells.
Results and Discussion
RNP CpG island fragments enhance transgene expression and confer resistance to silencing when linked to the hCMVpromoter
Ideally, for large-scale manufacture of protein therapeutics clonal cell lines producing the proteins are expanded without drug selection from a master cell bank. Where proteins are manufactured for use in humans the regulatory authorities require evidence that the manufacturing process gives production that is stable (i.e that falls within defined specification limits) over 25 to 30 generations of culture. To investigate the suitability of vectors containing the RNP CpG island fragments for this purpose, four clonal lines generated with the 8.0 kb RNP-EGFP construct and showing median expression that exceeded 5000 fluorescence units after 118 generations of culture in the presence of G418, were cultured with and without drug selection for a further 213 generations. For all four clones no reduction was observed in the percentage of cells showing expression exceeding 1000 fluorescence units after 213 generations of culture with drug selection. Also for all four clones no reduction was observed in the percentage of such cells after 38 generations without drug selection. Slight instability of expression was observed for one clone, #54, on very prolonged culture without drug selection. As shown in Figure 4B for this clone the percentage of cells showing expression exceeding 1000 units declined from 95% to 79% between 38 and 213 generations, while for the other three clones, exemplified by #67, no such decline was observed.
RNPCpG island vectors give improved yields of recombinant proteins in CHO cells
Clonal CHO-K1 lines were derived from transfectants generated with the hCMV-EPO and 8.0 kb RNP-EPO expression constructs. Twenty clones were chosen at random and assessed for EPO production (Figure 5B). For clones derived with hCMV-EPO, 6/20 produced no detectable EPO and only 1/20 (C4) showed a yield (0.85 μg/ml) exceeding 0.5 μg/ml. In marked contrast, 20/20 clones harbouring 8.0 kb RNP-EPO showed detectable EPO production, 18/20 produced more than 0.5 μg/ml, 16/20 produced more than 1 μg/ml, and one clone (R16) produced almost 14 μg/ml. Thus inclusion of the 8.0 kb RNP fragment in the expression construct resulted in the facile isolation of clones with improved EPO production, the average yield for the twenty clones being twenty-one-fold higher than with hCMV-EPO, and the best producing clone with 8.0 kb RNP-EPO giving sixteen-fold higher productivity than C4, the highest producing hCMV-EPO line.
Increased expression with RNP CpG island vectors is not due to increased transgene copy number
The possibility that CpG island vectors give improved transgene expression through integration at increased copy number was evaluated by conducting copy number analysis on genomic DNA for clonal lines expressing EGFP following transfection with hCMV-EGFP (13 lines) or 8.0 kb RNP-EGFP (9 lines). All these lines proved to have copy numbers of two or three. The highest expressing clones with both constructs had a copy number of three, but so did some of the lowest expressing clones for both constructs. Overall, statistical analysis of variance (by the ANOVA single factor method) indicated no significant correlation between level of expression and copy number for either construct.
The hCMV promoter has been by far the most commonly used promoter for high level transgene expression in mammalian cells, for a wide range of applications that includes the production of protein therapeutics in cultured cells, transgenic animals and gene therapies. Its utility in expressing transgenes for all these applications, however, has been hindered by its susceptibility to silencing, largely through effects involving adverse chromatin structure. For example, the isolation of clonal cell lines or transgenic animals showing stable, high level expression of transgenes is usually a slow and labour-intensive procedure because most integration events lead to silencing.
The results we report here show that incorporating a RNP CpG island fragment immediately upstream of the hCMV promoter gives major benefits in expression from the latter. These benefits include a substantial increase in the median level of expression observed in pools of transfectants, together with a substantial improvement in the proportion of cells in the pool that express. The CpG island fragments reproducibly gave 20 to 40-fold increases in the level of expression observed. With both EGFP and EPO these dramatically increased expression levels were maintained through at least 100 generations of subculture. The CpG island fragments also enabled the rapid and facile isolation of clonal cell lines showing stable, high level expression of EGFP and EPO.
Our previous work  showed that a 16 kb DNA fragment containing the RNP CpG island conferred resistance to heterochromatin-mediated silencing of expression from the endogenous RNP promoter and reduced position effect variegation, giving very consistent expression levels in tissue culture cells. In the studies we report here, constructs with the 8.0 kb RNP CpG island fragment preceding the hCMV promoter gave detectable levels of transgene expression for all integration events in which the construct remained intact, together with substantial increases in the level of expression from the hCMV promoter. Analysis of variance (by the single factor ANOVA method) showed these increases to be statistically significant (p = 8.13E-27). These constructs, however, gave much greater variability in levels of expression than those observed in our previous work with a larger CpG island fragment and the endogenous RNP promoter. It is not clear whether the greater variability in expression level for the CpG island constructs in the studies we report here than our previous ones is due to the use of a different promoter or different cell line, or occurs because sequences giving more complete isolation from the effects of chromatin structure or transcriptional activity adjacent to the integration site are present on the 16 kb fragment but not on the 8 kb fragment.
The present results demonstrate two very important applications of this novel transgene expression technology. One is the rapid production of recombinant proteins, in the quantities required for basic research, drug discovery and preclinical studies, using stable pools of transfectants. The CpG island technology circumvents the need for slow, labour intensive screening of clonal lines for this purpose. The other is faster and easier identification of clonal cell lines that show stable, high level production as candidates for large scale manufacture of protein therapeutics. With the CpG island technology screening of only 20 clonal CHO cell lines was sufficient to identify lines showing very high yields of EPO, the latter being a blockbuster protein drug that is widely used to treat anaemia associated with renal failure and chemotherapy. It is noteworthy that the hCMV and CHO cells used in these experiments are the promoter and cells most commonly used for commercial manufacture of protein therapeutics.
Through their capacity to confer an increase in the proportion of integration events that are productive, together with improvements in the level of transgene expression, RNP CpG island vectors have many other potential applications, including use in mammalian cell-based in vitro screens for drug discovery, transgenic animals for basic research and drug discovery, and gene therapy. For some of these applications, notably those involving transgene delivery with integrating viral vectors, gene expression elements of small size are required. The data we present here suggest that the 1.5 kb RNP fragment confers major benefits in expression level from the hCMV promoter. Efforts to further characterise and minimise these elements are ongoing, but the 1.5 kb fragment should be small enough for incorporation into most viral vectors.
The mechanism by which the RNP CpG island reduces silencing and improves transgene expression is under investigation in our laboratories. The data we report here show that the mechanism does not involve increasing the copy number of the integrated transgene. Our results to date, reported previously  and in this paper, are consistent with these elements being able to establish and maintain a more open chromatin domain irrespective of the local chromosome environment. We propose that the promoter-containing CpG-islands of housekeeping genes possess a chromatin remodelling function and that this is designated a "Ubiquitously-acting Chromatin Opening Element", or "UCOE".
hCMV-EGFP was vector pEGFP-N1 (Clontech, Cambridge, UK), which contains the hCMV promoter/enhancer on a 589 bp fragment. RNP CpG island-containing vectors were constructed by inserting genomic fragments from the RNP locus into the blunted Ase I site of hCMV-EGFP. These fragments were blunted versions of the 8.0 kb Hind III fragment, 4.0 kb BamH I-Hind III fragment and 1.5 kb Esp3I fragments to give 8.0 kb RNP-EGFP, 4.0 kb RNP-EGFP and 1.5 kb RNP-EGFP respectively (Figure 1B).
The erythropoietin (EPO) cDNA was isolated by PCR amplification from a Quick Clone Foetal Liver cDNA library (Clontech, Cambridge, UK). The resulting 705 bp product was subcloned using the TA-cloning vector pCR3.1 (Invitrogen, Paisley, UK) generating pCR-EPO. hCMV-EPO was constructed by subcloning an NheI-NotI fragment from pCR-EPO into the respective sites within the vector pEGFP-NI. 8.0 kb RNP-EPO was constructed by subcloning the blunt-ended 8.0 kb Hind III fragment into the blunted Ase I site of hCMV-EPO (Figure 1B).
Cell lines and transfections
CHO-K1 cells were grown in HAMS F12 (Invitrogen, Paisley, UK) plus 4500 mg/l L-ananyl-L-glutamine, 10 μg/ml each of penicillin and streptomycin, and 10% (v/v) heat inactivated foetal calf serum (FCS; Invitrogen, Paisley, UK). Transfection was carried out by electroporation using approximately 107 cells from 80% confluent cultures and a BioRad Gene Pulser II ™ set to deliver a single pulse of 975 μF at 250 V. Transfections used 1 μg of linearised hCMV plasmid and equivalent molar quantities for expression vectors of different size. Stably transfected cells were selected and maintained in growth medium containing 400 μg/ml geneticin sulphate (G418; Sigma, Poole, UK). Clonal cell lines were derived from stable transfected pools by standard limiting dilution techniques.
Quantification of transgene expression
Analysis of cells transfected with EGFP reporter constructs was with a Becton-Dickinson FACScan using the parental CHO-K1 cell line as a background, autofluorescence control. For EPO quantitation cells were seeded at 106 cells/well in 6-well plates and incubated in FCS-containing medium over 48 hours. Conditioned medium samples were assayed for EPO using a Quantikine IVD ELISA kit (R&D Systems Europe, Abingdon, UK)
Transgene copy number analysis
Copy number was determined by quantitative PCR (QPCR) using oligonucleotide primers and Beacon probes designed using Beacon Designer v2.0 software (Premier Biosoft International, CA, USA) specific to hCMV or EGFP sequences and to the endogenous housekeeping gene β-actin as a copy number control. Multiplex QPCR reactions containing optimised oligonucleotide and probe concentrations and ~500 ng of template DNA were performed on the MX4000™ multiplex PCR quantitative PCR system according to the manufacturers protocol (Stragene, La Jolla, CA), and subsequent data manipulations performed using the MX4000™ analysis software (Stratagene, La Jolla, CA). Copy number was assigned by comparison of the hCMV and/or EGFP: β-actin endpoint fluorescence ratio with that of a verified single copy integrant.
This work was partially funded under the UK Department of Trade and Industry LINK programme with support from the Medical Research Council and Biotechnology and Biological Sciences Research Council.
- Razin A: CpG methylation, chromatin structure and gene silencing – a three-way connection. EMBO. 1998, 17: 4905-4908. 10.1093/emboj/17.17.4905.View ArticleGoogle Scholar
- Bird AP, Wolffe AP: Methylation-induced repression – belts, braces, and chromatin. Cell. 1999, 99: 451-454. 10.1016/S0092-8674(00)81532-9.View ArticleGoogle Scholar
- Fusenegger M, Bailey JE, Hauser H, Mueller P: Genetic optimization of recombinant glycoprotein production by mammalian cells. Trends Biotech. 1999, 17: 35-42. 10.1016/S0167-7799(98)01248-7.View ArticleGoogle Scholar
- Doerfler W, Schubbert R, Heller H, Kammer C, Hilger-Eversheim K, Knoblauch M, Remus R: Integration of foreign DNA and its consequences in mammalian systems. Trends Biotech. 1997, 15: 297-301. 10.1016/S0167-7799(97)01061-5.View ArticleGoogle Scholar
- Furth PA, Hennighausen L, Baker C, Beatty B, Woychick R: The variability in activity of the universally expressed human cytomegalovirus immediate early gene 1 promoter/enhancer in transgenic mice. Nucleic Acids Res. 1991, 19: 6205-8.View ArticleGoogle Scholar
- Houdebine LM: Transgenic animal bioreactors. Transgenic Res. 2000, 9: 301-304. 10.1023/A:1008934912555.View ArticleGoogle Scholar
- Kuriyama S, Sakamoto T, Kikukawa M, Nakatani T, Toyokawa Y, Tsujinoue H, Ikenaka K, Fukui H, Tsujii T: Expression of a retrovirally transduced gene under control of an internal housekeeping gene promoter does not persist due to methylation and is restored partially by 5-azacytidine treatment. Gene Ther. 1998, 5: 1299-1305. 10.1038/sj.gt.3300738.View ArticleGoogle Scholar
- Mountain A: Gene therapy – the first decade. Trends Biotech. 2000, 18: 119-128. 10.1016/S0167-7799(99)01416-X.View ArticleGoogle Scholar
- Antoniou M, Harland L, Mustoe T, Williams S, Holdstock J, Yague E, Mulcahy T, Griffiths M, Edwards S, Ioannou PA, Mountain A, Crombie R: Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. Genomics. 2003, 82: 269-279. 10.1016/S0888-7543(03)00107-1.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.